Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 11/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.49 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1950394 | 0.99 | SLC6A2 (0.48) | SLC6A2SLC6A3SLC6A4MAOBMAOA | |
| SCHEMBL3185506 | 0.96 | SLC6A4 (0.53) | SLC6A2SLC6A3SLC6A4MAOB | |
| SCHEMBL3185502 | 0.96 | SLC6A4 (0.53) | SLC6A2SLC6A3SLC6A4MAOB | |
| SCHEMBL3206669 | 0.82 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4MAOBMAOA | |
| SCHEMBL3396461 | 0.80 | NPC1 (0.58) | SLC6A2SLC6A3SLC6A4MAOBNPC1 | |
| SCHEMBL3396463 | 0.80 | NPC1 (0.58) | SLC6A2SLC6A3SLC6A4MAOBNPC1 | |
| SCHEMBL1951924 | 0.80 | SLC6A4 (0.56) | SLC6A2SLC6A3SLC6A4MAOBMAOA | |
| Hydrochloric Acid SCHEMBL1951921 | 0.79 | SLC6A4 (0.55) | SLC6A2SLC6A3SLC6A4MAOBMAOA | |
| SCHEMBL1949772 | 0.78 | MAOB (0.40) | MAOBMAOANPC1RAB9A | |
| SCHEMBL1949774 | 0.78 | MAOB (0.40) | MAOBMAOANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136854-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-06-09 | — | — | US | claimed |
| US-20110136854-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-06-09 | — | — | US | disclosed |
| EP-2242754-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NeuroSearch A/S (DK) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009098209-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136854-A1 | NOVEL 9-AZA-BICYCLO[3.3.1]NON-3-YLOXY CHROMEN-2-ONE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A3 7/4885SLC6A4 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.